|
August 3, 2023
|
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
|
|
August 2, 2023
|
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
|
|
July 27, 2023
|
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
|
|
July 17, 2023
|
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
|
|
July 5, 2023
|
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
|
|
June 28, 2023
|
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
|
|
June 26, 2023
|
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
|
|
June 14, 2023
|
Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules
|
|
June 13, 2023
|
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
June 8, 2023
|
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
|